PCSK9 and Obesity: Furthermore, liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been used clinically as anti-diabetic and anti-obesity treatment, which has also been identified as a potent suppressor of PCSK9 expression, explaining at least partly its beneficial effect on CVDs [150].